Raltegravir
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Human Immunodeficiency Virus (HIV) Infection
Conditions
Human Immunodeficiency Virus (HIV) Infection
Trial Timeline
Sep 27, 2018 → Oct 23, 2018
NCT ID
NCT03667547About Raltegravir
Raltegravir is a approved stage product being developed by Merck for Human Immunodeficiency Virus (HIV) Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03667547. Target conditions include Human Immunodeficiency Virus (HIV) Infection.
What happened to similar drugs?
13 of 20 similar drugs in Human Immunodeficiency Virus (HIV) Infection were approved
Approved (13) Terminated (4) Active (7)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00377065 | Pre-clinical | Completed |
| NCT03732625 | Approved | UNKNOWN |
| NCT03667547 | Approved | Completed |
| NCT03374358 | Approved | Completed |
| NCT02097108 | Phase 2 | Completed |
| NCT01978743 | Pre-clinical | Completed |
| NCT01767701 | Phase 2 | Completed |
| NCT01453933 | Approved | UNKNOWN |
| NCT01620736 | Phase 2 | Withdrawn |
| NCT01453192 | Phase 3 | Completed |
| NCT01448486 | Approved | Terminated |
| NCT01327482 | Pre-clinical | Completed |
| NCT01325051 | Phase 1 | Completed |
| NCT01042652 | Pre-clinical | UNKNOWN |
| NCT01164605 | Pre-clinical | UNKNOWN |
| NCT01087840 | Approved | Completed |
| NCT01027182 | Phase 1 | Completed |
| NCT00939874 | Approved | Completed |
| NCT00807443 | Phase 2 | Completed |
| NCT00887653 | Phase 3 | Completed |
Competing Products
20 competing products in Human Immunodeficiency Virus (HIV) Infection